Kidswell Bio Corporation (TYO:4584)

Japan · Delayed Price · Currency is JPY

170.00

+4.00 (2.41%)

Oct 6, 2026, 3:30 PM JST

Market Cap	8.60B -25.7%
Revenue (ttm)	6.14B -2.9%
Net Income	-373.13M
EPS	-7.56
Shares Out	50.59M
PE Ratio	n/a
Forward PE	7.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	276,000
Open	166.00
Previous Close	166.00
Day's Range	165.00 - 171.00
52-Week Range	125.00 - 320.00
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly k... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 32

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4584

Full Company Profile

Financial Performance

In fiscal year 2026, Kidswell Bio's revenue was 6.59 billion, an increase of 29.65% compared to the previous year's 5.08 billion. Losses were -413.00 million, 1866.7% more than in 2025.

Financial Statements